Get intelligentvalue.com

Own it today or select a payment plan

Secured by Stripe

Premium Domain Name

intelligentvalue.com

intelligentvalue.com logo

is available for purchase

246 views
Visitors fromUSUS 53%·AUAU 33%·ININ 7%·GBGB 2%·FRFR 1%

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

VisaMastercardAmerican ExpressDiscoverDiners ClubJCBApple PayGoogle Pay

Immuron CEO Steven Lydeamore Investor Webinar Presentation

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday, 14th November, 2023, 1:00pm AEDT/10:00am AWST.

CEO Steven Lydeamore will provide an overview and update on the business and upcoming milestones.

Following the presentation, attendees will have the opportunity to ask questions directly to Mr Lydeamore during a moderated Q & A session.

This webinar can be viewed live via zoom & you register via the link below.

Zoom: https://share.hsforms.com/1ccfJimCATYqzCkvIKIC7VAd16zr

A recorded copy of the webinar and presentation will be available on the Company’s website following the event.

Authorised for release by the Board of Immuron Limited.

COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
 

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN) is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: http://www.immuron.com


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  276.35
+2.80 (1.02%)
AAPL  286.14
+1.96 (0.69%)
AMD  414.01
+58.75 (16.54%)
BAC  53.77
+0.66 (1.23%)
GOOG  395.94
+11.67 (3.04%)
META  613.79
+8.83 (1.46%)
MSFT  413.01
+1.63 (0.40%)
NVDA  204.65
+8.15 (4.15%)
ORCL  191.72
+6.38 (3.44%)
TSLA  398.63
+9.26 (2.38%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.